Market News

Uniti Group Inc. (UNIT) Analysts See $0.62 EPS; Silence Therapeutics plc (LON:SLN) Had 2 Analysts Last Week

Silence Therapeutics plc (LON:SLN) Logo

Analysts expect Uniti Group Inc. (NASDAQ:UNIT) to report $0.62 EPS on May, 10 after the close.They anticipate $0.03 EPS change or 4.62% from last quarter’s $0.65 EPS. UNIT’s profit would be $111.56 million giving it 6.59 P/E if the $0.62 EPS is correct. After having $0.64 EPS previously, Uniti Group Inc.’s analysts see -3.13% EPS growth. The stock decreased 3.54% or $0.6 during the last trading session, reaching $16.35. About 1.49 million shares traded. Uniti Group Inc. (NASDAQ:UNIT) has declined 35.45% since April 21, 2017 and is downtrending. It has underperformed by 47.00% the S&P500.

Among 2 analysts covering Silence Therapeutics PLC (LON:SLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Silence Therapeutics PLC had 12 analyst reports since September 29, 2015 according to SRatingsIntel. On Thursday, February 1 the stock rating was maintained by Peel Hunt with “Buy”. The company was maintained on Tuesday, April 3 by Peel Hunt. The rating was maintained by Canaccord Genuity on Tuesday, December 20 with “Buy”. The firm has “Buy” rating given on Monday, March 26 by Peel Hunt. Peel Hunt maintained Silence Therapeutics plc (LON:SLN) rating on Monday, January 22. Peel Hunt has “Buy” rating and GBX 275 target. As per Tuesday, September 29, the company rating was maintained by Canaccord Genuity. The stock has “Buy” rating by Peel Hunt on Thursday, December 28. The stock of Silence Therapeutics plc (LON:SLN) earned “Buy” rating by Canaccord Genuity on Thursday, August 11. The firm has “Buy” rating given on Monday, January 9 by Canaccord Genuity. The stock of Silence Therapeutics plc (LON:SLN) earned “Buy” rating by Canaccord Genuity on Tuesday, September 27. See Silence Therapeutics plc (LON:SLN) latest ratings:

03/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 277.00 Maintain
26/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 277.00 New Target: GBX 277.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
22/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
08/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 276.00 New Target: GBX 276.00 Maintain
28/12/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
14/12/2017 Broker: Peel Hunt Rating: Buy New Target: GBX 276.00 Initiates Starts

The stock increased 2.97% or GBX 5 during the last trading session, reaching GBX 173.5. About 5,170 shares traded. Silence Therapeutics plc (LON:SLN) has 0.00% since April 21, 2017 and is . It has underperformed by 11.55% the S&P500.

Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company has market cap of 121.49 million GBP. The firm creates short interfering RNA molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It currently has negative earnings. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Uniti Group Inc., an internally managed real estate investment trust, engages in the acquisition and construction of mission critical communications industry in the United States and Mexico. The company has market cap of $2.94 billion. It operates in four business divisions: Leasing, Fiber Infrastructure, Towers, and Consumer CLEC. It currently has negative earnings. The firm engages in the acquisition and leasing of mission-critical communications assets, such as fiber, data centers, consumer broadband, coaxial and upgradeable copper assets.

Uniti Group Inc. (NASDAQ:UNIT) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *